The PennZone

  • Home
  • Non-profit
  • Health
  • Books
  • Business
  • Entertainment
  • Legal
  • Marketing
  • Financial

ExpressCells Named Most Fundable Company by Pepperdine Graziadio Business School
The PennZone/10088820

Trending...
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
PHILADELPHIA - PennZone -- ExpressCells, Inc., a biotechnology company that creates advanced cell lines for research, was awarded a silver designation on the Pepperdine Graziadio Business School's third annual Most Fundable Companies® List. ExpressCells competed against over 4,500 early-stage U.S. startups spanning all 50 states, all with less than $10 million in annual revenue, to be named among a list of twenty. The Most Fundable Companies initiative is designed to recognize exceptional entrepreneurs who are solving today's problems with inventive solutions and are also seeking investment capital to fuel their company's growth.

"Since starting ExpressCells in 2018, we've been focused on helping biological researchers conduct better experiments.. The Most Fundable Companies initiative provided us with a data-driven analysis that we have already incorporated into our fundraising activities," said Matt Handel, CEO. "It's validating that Pepperdine Graziadio Business School recognizes entrepreneurs throughout the country and provides resources to assist startups in securing private capital to accelerate meaningful innovation across industries and communities."

More on The PennZone
  • TOKSTAR Welcomes NBA 2K Star Young Wayne
  • Matt Zavala of Zavala Law, PC Elected to Ventura County Bar Association Board of Directors
  • Prolific Press Opens Full-Length Book Submissions for Poetry, Fiction and Non-Fiction
  • Clear Path Landscaping Announces Commercial and Residential Snow Removal for 2026-27 Season
  • Montana Artist Ryan Jolley Receives Goodman Award at Mountain Oyster Club Art Show

The Most Fundable Companies initiative involved a multi-phase assessment that evaluated several company variables, including financial projections, market opportunity, intellectual property, and the strength of the management team, all of which were used to produce a fundability score. The Most Fundable Companies were evaluated and selected based on their readiness for private investment. Most Fundable Companies is powered by The Venture Alliance.

As a winner on the Most Fundable Companies List, ExpressCells will be profiled on Entrepreneur.com and be featured in the December print issue of the magazine. For a complete list of the winners, visit www.pepperdine.edu/mfc-list, where you can vote for ExpressCells as the "crowd favorite" through November 1.

The Pepperdine Most Fundable Companies list does not represent an offer to sell securities. It neither constitutes investment advice, nor is an endorsement of any particular product or service. Pepperdine University is not a broker-dealer and does not perform services provided by a broker-dealer, including but not limited to any financial or investment advising.

More on The PennZone
  • Make Your Move to Luxury Living at Heritage at Hopewell with Rates Starting at Just 3.750% (5.803% APR)
  • Scott Glickson Joins STS Capital Partners as Managing Director
  • BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth
  • PinnacleQM launches new enterprise website to help Australian organisations deliver more with confidence

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its uses it proprietary genome editing technology, in combination with CRISPR/Cas9, to create advanced, knock-in cell lines to enhance drug discovery and other biological research. It shortens the time for delivery of knock-in cell lines by up to 75% relative to current technologies. The speed of the process allows ExpressCells to insert one to three genes into the same cell line. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines.

ExpressCells' genetic engineering technology was invented at the Temple University School of Pharmacy by Oscar Perez-Leal, MD. ExpressCells holds a global, exclusive license on this technology. For more information, visit xpresscells.com (http://www.xpresscells.com/).

Contact
Matt Handel
***@xpresscells.com


Source: ExpressCells

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • 20-Year Crash Cost of Signalized RC3 Cloverleaf Could Exceed $25 Million
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
  • BitTitan Expands MigrationWiz with SharePoint Sites Migration and Simplified Collaboration Licensing
  • Olympic champion Katie Moon to compete at Pole Vault in Paradise in Key West
  • Smith Strong Merges With Gravis Law, Bringing Gravis Law to Virginia
  • Angela's Boutique Highlights Self-Care Gifts for Philadelphia Holiday Shoppers
  • Turkish Engineer Who Cracked Wall Street's Algorithm Launches Hermes AI Analyzer
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
  • Veteran Antiques Expert John Swahn Releases New Book: The Truth About Antiques
  • Steven Weisz of Art Imagined Photography to exhibit at ExpoMetro Florence, Italy
  • Hope Survives Managing Director Jasmine Balignasay-Chavez Receives 2026 Catalyst Award
  • LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
  • Security Planning Tips For Your Holiday Event From Access Patrol Services

Popular on PennZone

  • ALight Technology And Services Limited Advances Through Peachscore + Dealum Accelerator and Join LvlUp Labs - 184
  • Hunter's Garage Teams Up With The Small Batch for a Free Thanksgiving Meal - 174
  • WebDrafter Welcomes Dreamwork Exteriors as a New Marketing Client - 143
  • Conservative Latinos for PA PAC Endorses Stacy Garrity for Governor: "Pennsylvania's Latino Families Need a Leader Who Delivers" - 111
  • Communities In Schools of Eastern Pennsylvania Honors United Way and Local Leaders - 103
  • Charlie Shaw and Patrick Carragher win SEO Agency of the Year 2026
  • RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
  • Alan Hamilton of Shiver Hamilton Campbell Inducted as a Fellow of the American College of Trial Lawyers
  • Pastor Carlton L. Aiken Sr. Celebrates 55 Years with "Sermonic Selections"
  • No Bounds Digital Acquires Draidel's HubSpot Agency Business, Expanding Reach and Capabilities

Similar on PennZone

  • BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
  • Boston Industrial Solutions Introduces the New Volta® M100 Pad Printing Machine
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
  • New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
  • New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us